噻托溴铵与沙美特罗氟替卡松序贯治疗稳定期慢性阻塞性肺疾病的临床分析  

Clinical analysis of tiotropium bromide and salmeterol fluticasone in sequential therapy for stable chronic obstructive pulmonary disease

作　　者：邓创豪 邓琪武 梁惠贤 张丹婷 康奕飞 薛瑞君 刘付亮 

机构地区：[1]广州市海珠区中医医院,510220

出　　处：《中国实用医药》2017年第21期11-13,共3页China Practical Medicine

摘　　要：目的观察稳定期慢性阻塞性肺疾病(COPD)采用噻托溴铵与沙美特罗氟替卡松序贯治疗的临床疗效。方法 41例稳定期COPD患者,按照治疗方案的不同分为联合组(19例)与序贯组(22例)。联合组采用噻托溴铵干粉吸入剂+沙美特罗氟替卡松干粉吸入剂治疗,序贯组先使用噻托溴铵干粉吸入剂治疗,后改用沙美特罗氟替卡松干粉吸入剂治疗。比较两组患者急性发作次数、肺功能指标、6 min步行距离(6MWT),同时对过程中出现的药物不良反应、合并症进行对比分析。结果两组肺功能指标和6MWT比较,差异无统计学意义(P>0.05)。序贯组急性发作次数为(1.7±0.6)次,少于联合组的(3.2±0.8)次,差异具有统计学意义(P<0.05)。序贯组药物不良反应发生率为4.55%,合并症发生率为4.55%,均明显低于联合组的26.32%、31.58%,差异具有统计学意义(P<0.05)。结论对于稳定期COPD采用序贯治疗,患者的依从性更好,不良反应、合并症更低,经济负担更低。Objective To observe clinical effect by tiotropium bromide and salmeterol fluticasone in sequential therapy for stable chronic obstructive pulmonary disease （COPD）. Methods A total of 41 patients with stable COPD were divided by different treatment schemes into combined group （19 cases） and sequential group （22 cases）. The combined group received tiotropium bromide dry powder inhalant ＋ salmeterol fluticasone dry powder inhalant for treatment. The sequential group received initial treatment by tiotropium bromide dry powder inhalant, followed by salmeterol fluticasone dry powder inhalant for treatment instead. Comparison was made on acute attack times, pulmonary function indexes and 6 min walk test （6MWT） between the two groups. Adverse drug reactions and complications during treatment were taken into comparative analysis. Results There was no statistically significant difference of pulmonary function indexes and 6MWT between the two groups （/-〉0.05）. The sequential group had fewer acute attack times as （3.2 - 0.8） times than （1.7 -＋ 0.6） times in the combined group, and their difference had statistical significance （P〈0.05）. The sequential group had incidence of adverse drug reactions as 4.55% and incidence of complications as 4.55%, which were all obviously lower than 26.32% and 31.58% in the combined group, and their difference had statistical significance （P〈0.05）. Conclusion Implement of sequential therapy for stable COPD patients shows excellent compliance, low incidence of adverse reactions and complications, and light financial burden.

关 键 词：噻托溴铵 沙美特罗氟替卡松 序贯治疗 慢性阻塞性肺疾病 疗效 

分 类 号：R563.9[医药卫生—呼吸系统]